Heat Biologics Inc - Company & Market Research Reports

Heat Biologics is a biopharmaceutical company that develops novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. It is focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy), a cell-based immunotherapy for use in the treatment of a wide range of cancers. Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products. The company was founded in 2008 and is based in Durham, North Carolina.

Colorectal Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Colorectal Cancer Drug Development Pipeline Review, 2017

  • Report
  • 299 Pages
From
T-Cell Immunotherapy Market (2nd Edition), 2017-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

  • Report
  • 654 Pages
From
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 3085 Pages
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018 - Product Thumbnail Image

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1005 Pages
From
Transplantation Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Transplantation Drug Development Pipeline Review, 2017

  • Report
  • 242 Pages
From
Global & USA Cancer Immunotherapy Market Analysis & Forecast to 2022 - Product Thumbnail Image

Global & USA Cancer Immunotherapy Market Analysis & Forecast to 2022

  • Report
  • 370 Pages
From
Competitor Analysis: Cancer Vaccines - Product Thumbnail Image

Competitor Analysis: Cancer Vaccines

  • Report
  • 179 Pages
From
HIV / AIDS - Pipeline Review, H1 2016 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H1 2016

  • Drug Pipelines
  • 886 Pages
From
HIV / AIDS - Pipeline Review, H2 2015 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H2 2015

  • Drug Pipelines
  • 916 Pages
From
HIV-1 Infection - Pipeline Review, H2 2015 - Product Thumbnail Image

HIV-1 Infection - Pipeline Review, H2 2015

  • Drug Pipelines
  • 406 Pages
From
Non-Small Cell Lung Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

  • Drug Pipelines
  • 3034 Pages
From
HIV / AIDS - Pipeline Review, H1 2015 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H1 2015

  • Drug Pipelines
  • 871 Pages
From
HIV-1 Infection - Pipeline Review, H1 2015 - Product Thumbnail Image

HIV-1 Infection - Pipeline Review, H1 2015

  • Drug Pipelines
  • 319 Pages
From
Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025 - Product Thumbnail Image

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

  • Report
  • 401 Pages
From
Global & USA Cancer Immunotherapy Market Analysis to 2020 - Updated Edition - Product Thumbnail Image

Global & USA Cancer Immunotherapy Market Analysis to 2020 - Updated Edition

  • Report
  • 317 Pages
From
Heart Transplant Rejection - Pipeline Review, H1 2018 - Product Thumbnail Image

Heart Transplant Rejection - Pipeline Review, H1 2018

  • Drug Pipelines
  • 32 Pages
From
Cancer Vaccines: Technologies and Global Markets - Product Thumbnail Image

Cancer Vaccines: Technologies and Global Markets

  • Report
  • 183 Pages
From
Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030 - Product Thumbnail Image

Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030

  • Report
  • 314 Pages
From
Global Immunotherapy Drugs 2016-2020 - Product Thumbnail Image

Global Immunotherapy Drugs 2016-2020

  • Report
  • 159 Pages
From
Loading Indicator
adroll